Further studies are warranted for analysing the potential value of CCL5, CXCL9 and IFN-ɣ as biomarkers of response to trastuzumab-deruxtecan and the possible synergism between trastuzumab-deruxtecan and tumor-infiltrating NK cells. The gene discussed is CXCL9; the disease is neoplasm.